Org 33201
Org 33201 is an orally active and selective Aromatase inhibitor with an IC50 of 2.2 nM. Org 33201 inhibits the activity of Aromatase by binding to its heme iron. Org 33201 can be used in the study of estrogen-dependent diseases (such as postmenopausal breast cancer).
For research use only. We do not sell to patients.
- CAS No.: 148714-92-5
- Formula: C21H29ClN2S
- Molecular Weight:376.99
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
Aromatase 2.2 nM (IC50) |
In Vitro
Org 33201 potently inhibits aromatase activity in human placental microsomes, with an IC50 of 2.2 nM, and acts as a competitive inhibitor by binding to heme iron[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Chemical Information
-
CAS No. 148714-92-5
-
Molecular Weight 376.99
-
Formula C21H29ClN2S
-
SMILES
C(C)[C@@]12C=3C(=C(SCC)C=CC3CCC1)C[C@@H](CN4C=CN=C4)C2.Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)